Skyrizi
NDC 0074-2042
Product Information
Skyrizi is a BLA-approved product labeled by Abbvie Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 0074-2042 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0074-2042?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- RISANKIZUMAB (UNII: 90ZX3Q3FR7)
- RISANKIZUMAB (UNII: 90ZX3Q3FR7) (Active Moiety)
- ISOPROPYL ALCOHOL (UNII: ND2M416302)
- ISOPROPYL ALCOHOL (UNII: ND2M416302) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SUCCINIC ACID (UNII: AB6MNQ6J6L)
- SORBITOL (UNII: 506T60A25R)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- WATER (UNII: 059QF0KO0R)
- SODIUM SUCCINATE HEXAHYDRATE (UNII: U16QOD6C4E)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2166136 - risankizumab-rzaa 75 MG in 0.83 mL Prefilled Syringe
- RxCUI: 2166136 - 0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe
- RxCUI: 2166136 - risankizumab-rzaa 75 MG per 0.83 ML Prefilled Syringe
- RxCUI: 2166137 - {2 (0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe) } Pack
- RxCUI: 2166137 - risankizumab-rzaa 75 MG in 0.83 mL (2) Prefilled Syringe Pack
* Please review the full disclaimer at the bottom of this page.
Patient Education
Risankizumab-rzaa Injection
Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. It is also used to treat active psoriatic arthritis (condition that causes joint pain and swelling and scales on the skin) in adults. Risankizumab-rzaa injection is also used to treat Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults. Risankizumab-rzaa is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.
[Learn More]
* Please review the full disclaimer at the bottom of this page.